Sunbelt Securities Inc. Has $1.26 Million Holdings in Pfizer Inc. $PFE

Sunbelt Securities Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 30.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 49,426 shares of the biopharmaceutical company’s stock after selling 21,811 shares during the period. Sunbelt Securities Inc.’s holdings in Pfizer were worth $1,259,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer in the 3rd quarter worth about $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the second quarter worth about $30,000. True Wealth Design LLC increased its stake in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 974 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Pfizer in the second quarter valued at approximately $32,000. Finally, Evelyn Partners Asset Management Ltd bought a new position in Pfizer in the 2nd quarter valued at approximately $33,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline — Pfizer reported positive topline results from the Phase 3 TALAPRO-3 study showing TALZENNA (talazoparib) plus XTANDI (enzalutamide) significantly improved radiographic progression‑free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer, a meaningful late‑stage win that could expand a high‑value oncology franchise. TALAPRO-3 Topline
• Positive Sentiment: Mid‑stage breast cancer data supports pipeline — Pfizer’s Phase 2 FOURLIGHT‑1 trial of atirmociclib met its primary endpoint in second‑line HR+/HER2‑ metastatic breast cancer, cutting risk of progression and strengthening Pfizer’s bid to follow on from CDK4/6 leaders (Ibrance, etc.). This readout is being positioned as a key oncology catalyst. Atirmociclib Phase 2 Results
• Positive Sentiment: Analyst upgrade and price‑target lift — HSBC raised its price target to $32 and moved to a buy rating, citing upside to Pfizer’s valuation; that upgrade has drawn investor attention and provided near‑term support. HSBC Upgrade
• Neutral Sentiment: Early‑stage liver program advanced — Pfizer updated progress on a Phase 1 PF‑07328948 liver study, which modestly supports the pipeline but is an early, lower‑visibility catalyst. PF‑07328948 Liver Study
• Neutral Sentiment: Public commentary and investor interest — Media/columnist coverage (including Jim Cramer) and various valuation pieces have increased attention on PFE, driving trading volume but not a clear directional catalyst. Cramer & Media Coverage
• Negative Sentiment: Program trimming: early‑stage melanoma study ended — Pfizer discontinued an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and tempers the otherwise bullish pipeline narrative. Melanoma Study Stop
• Negative Sentiment: Industry pricing scrutiny — A Reuters/analysis piece on TrumpRx highlights continued political scrutiny of U.S. drug prices; broader policy and pricing headlines can pressure large pharma multiples and investor sentiment for companies like Pfizer. TrumpRx Pricing Analysis

Pfizer Stock Down 0.5%

Shares of NYSE:PFE opened at $27.33 on Thursday. The firm has a market cap of $155.38 billion, a P/E ratio of 20.09 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The business’s 50 day simple moving average is $26.61 and its two-hundred day simple moving average is $25.57. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.63 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on PFE. BMO Capital Markets reissued an “outperform” rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Bank of America decreased their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Morgan Stanley set a $27.00 price target on Pfizer and gave the stock a “positive” rating in a report on Tuesday. Finally, Royal Bank Of Canada assumed coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.14.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.